Pregabalin Market by Application (Epilepsy, Neuropathic Pain, Fibromyalgia, and Generalized Anxiety Disorder) and End User (Research Institutes, Pharmaceutical Companies, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025

Get 20% Free Customization In This Report

Medical Devices & Supplies	LI_182652	Pages: NA	May 2019 \| 2063 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Pregabalin is an anticonvulsant drug used for the treatment of epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its mode of action involves decrease in pain signals sent by the damaged nerves in the body.

Increase in geriatric population suffering from neuropathic diabetes and rise in prevalence of diabetes, HIV, cancer, epilepsy, fibromyalgia, and other such disorders are expected to drive the Pregabalin market. According to the Global Year Against Neuropathic Pain 2014-2015 report by International Association of the Study of Pain, around 7%8% of adults suffer from chronic pain with neuropathic characteristics. Furthermore, Pfizers patent expiry of Lyrica (Pregabalin) in 2018 is anticipated to increase the market share of generic manufacturing companies in the UK.

However, stringent government regulations, lack of awareness about neuropathic pain, presence of substitutes of Pregabalin such as gabapentin, and adverse drug effects hinder the market growth. High investment in developing nations are proving new opportunities for the market players.

The Pregabalin market is segmented on the basis of application, end user, and geography. Based on application, the market is divided into epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Based on the end user, it is classified into research institutes, pharmaceutical companies, and others (hospitals and clinics). Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

The study provides an in-depth analysis of the global Pregabalin market, with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report presents a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand various products of the market.
Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.

Pregabalin Market Key Segments:

By Application

Epilepsy
Neuropathic Pain
Fibromyalgia
Generalized Anxiety Disorder

By End User

Research Institutes
Pharmaceutical Companies
Others (Hospitals and Clinics)

By Geography

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East
- Africa

List of players profiled in the report

Pfizer Inc.
Torrent Pharmaceuticals Ltd.
Lupin Limited
Zydus Cadila Healthcare Ltd.
Cipla Limited
Genesis Remedies
Sanofi
Medley Pharmaceuticals Limited
Genesis Biotec Inc.
Biomax

"Note : The list of companies mentioned in the description is tentative in nature and may change after detailed analysis."

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 PREGABALIN MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. EPILEPSY

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. NEUROPATHIC PAIN

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. FIBROMYALGIA

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. GENERALIZED ANXIETY DISORDER

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

Chapter: 5 PREGABALIN MARKET, BY END USER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. RESEARCH INSTITUTES

5.2.1. Market size and forecast

5.3. PHARMACEUTICAL COMPANIES

5.3.1. Market size and forecast

5.4. OTHERS

5.4.1. Market size and forecast

Chapter: 6 PREGABALIN MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Pregabalin Market by Application
6.2.5. North America Pregabalin Market by End-User

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Pregabalin Market by Application
6.3.5. Europe Pregabalin Market by End-User

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Pregabalin Market by Application
6.4.5. Asia-Pacific Pregabalin Market by End-User

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Latin America market size and forecast
6.5.3.2. Middle East market size and forecast
6.5.3.3. Africa market size and forecast

6.5.4. LAMEA Pregabalin Market by Application
6.5.5. LAMEA Pregabalin Market by End-User

Chapter: 7 COMPANY PROFILES

7.1. PFIZER INC.

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. TORRENT PHARMACEUTICALS LTD

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. LUPIN LIMITED

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. ZYDUS CADILA HEALTHCARE LTD

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. CIPLA LIMITED

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. GENESIS REMEDIES

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. SANOFI

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. MEDLEY PHARMACEUTICALS LIMITED

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. GENESIS BIOTEC INC

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. BIOMAX

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

"Note : The list of companies mentioned in the description is tentative in nature and may change after detailed analysis."

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Shopping Cart is Empty..

Your Shopping Cart Is Empty

Pregabalin Market by Application (Epilepsy, Neuropathic Pain, Fibromyalgia, and Generalized Anxiety Disorder) and End User (Research Institutes, Pharmaceutical Companies, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025